Methcathinone
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Methcathinone (ephedrone) — cat — is a synthetic stimulant of the cathinone class. It is the β-keto structural analog of methamphetamine, roughly twice as potent as amphetamine in animal models.[1] It forces dopamine and norepinephrine out of nerve terminals into the synapse, flooding the brain's reward and arousal circuits.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized in 1928, it was briefly explored as an antidepressant in the Soviet Union but never reached clinical use.[4][5] Clandestine production spread through the USSR in the 1970s and reached US markets by the late 1980s, prompting Schedule I placement in 1993.[6] Today it is internationally controlled, its reputation shaped by a devastating epidemic of permanent brain damage among IV users across Eastern Europe.[7]
Subjective effects include euphoria, driven energy, heightened confidence, wakefulness, and a strong compulsive compulsive redosing urge.[8][5] The experience is focused, alert stimulation — closer to Amphetamine's push than mephedrone's warmth, with little emotional openness. Anxiety, paranoia, and agitated overstimulation are characteristic at higher doses and with prolonged use.
Methcathinone produces dependence with compulsive redosing; brain imaging in abstinent users shows lasting damage to dopamine-processing circuits.[9] The gravest risk is route-specific: IV use of permanganate-synthesized product introduces manganese contamination causing permanent, treatment-resistant parkinsonism — standard treatments do not work.[10][7] The evidence base rests on animal studies and the Eastern European epidemic literature; no controlled human trials exist.
History[edit]
Discovery
Methcathinone was first synthesized at Parke-Davis in 1928.[4] Soviet researchers evaluated it as a potential antidepressant through the 1930s and 1940s, but it never entered medical use.[4][5]
Illicit Spread and Scheduling
Clandestine production emerged in the Soviet Union in the 1970s, exploiting a straightforward synthesis: pseudoephedrine oxidized with potassium permanganate.[11][7] The compound appeared on US markets in the early 1990s — particularly in Michigan[12] — and the DEA placed it permanently in Schedule I in 1993.[6]
The Eastern European Epidemic
From the 1990s through the 2010s, intravenous methcathinone use spread across Estonia, Latvia, Ukraine, Poland, and other former Soviet states.[13][14] The defining consequence was not the stimulant but residual manganese from the synthesis — it accumulated in users' brains and produced a largely irreversible parkinsonian syndrome.[7][15]
The name "ephedrone" — predominant in Russian-language drug culture — reflects the compound's origin as an oxidation product of ephedrine or pseudoephedrine. In English, "cat" emerged as the primary street name during the early 1990s US epidemic. The compound's ease of synthesis from over-the-counter cold medication made it notably accessible, driving adoption among stimulant-seeking populations in Eastern Europe where it was described as cheaper and more available than amphetamine.[16]
Chemistry[edit]
Structural Class
Methcathinone is a synthetic cathinone — the β-keto structural analog of methamphetamine and the N-methyl derivative of cathinone, the stimulant alkaloid of the khat plant.
The β-keto group defines the cathinone class and distinguishes it from the amphetamine series. Despite this modification, methcathinone crosses the blood-brain barrier readily.[2]
Molecular Properties
| Molecular formula | C₁₀H₁₃NO |
| Molecular weight | 163.22 g/mol |
Pharmacology[edit]
Mechanism of Action
Methcathinone enters nerve terminals through the dopamine and norepinephrine transporters, then forces these neurotransmitters out into the synapse — a process called reverse transport. This floods the brain with dopamine and norepinephrine, directly producing the stimulant effects.[1][2][3] The mechanism is shared with amphetamine and methamphetamine.
Methcathinone acts almost exclusively on dopamine and norepinephrine. Its effect on the serotonin system is more than 63 times weaker,[3] making it a strongly catecholamine-selective stimulant — and this selectivity drives its high abuse potential.[17]
Pharmacokinetics
No human pharmacokinetic data exist for methcathinone. In animal models, effects appear within five minutes of injection and last roughly 60–90 minutes;[18] oral duration is estimated at four to six hours by analogy with the stimulant class.safety citation needed The compound and its metabolites are detectable in urine[19] and blood.[20]
Neuroscience[edit]
Where It Acts
Methcathinone floods the brain's main mesolimbic pathway — from the ventral tegmental area to the nucleus accumbens — by forcing dopamine into it.[21][22] This produces euphoria, drive, and heightened motivation. Simultaneous norepinephrine release elevates heart rate and blood pressure and generates the sense of alert arousal.
Why It Matters
The compulsive compulsive redosing urge reflects what methcathinone does to the brain's "wanting" system. Mesolimbic dopamine drives motivation toward the drug — not just pleasure, but a mounting need — even as the pleasurable return diminishes.[16][5] Animal studies show tolerance and sensitization developing simultaneously: the pleasure fades while the drive intensifies.[23]
The sole human neuroimaging study (n=4) found 16–24% reductions in striatal DAT density after approximately three years of abstinence.[9] Whether this replicates in larger samples, or whether the damage stabilizes after stopping, is unknown. Rat studies show prefrontal cortex synaptic damage and disruption of over 1,400 genes after subchronic exposure,[24] but no human imaging of these regions exists. The most basic question — the human dose-response curve — has never been studied.
Subjective Effects[edit]
Methcathinone delivers driven, catecholaminergic stimulation — energized euphoria, sharp confidence, and relentless wakefulness fueled by dopamine and norepinephrine. The defining quality is focused alertness with a nearly mechanical motivational drive, and a persistent urge to redose that most users describe as one of the most distinctive features of the experience.
Within the cathinone family, methcathinone sits closest to amphetamine and methamphetamine in character — more hard push than emotional warmth, with little of the empathogenic openness found in mephedrone or MDMA. The compulsive redosing urge is a defining behavioral feature consistent with its high dopamine selectivity.
Effect Grid
At common doses, the full stimulant experience is present: pronounced cognitive euphoria, strong motivation enhancement, marked thought acceleration, and significant wakefulness. Sociability and confidence are heightened. Users report increased energy and reduced fatigue, with a clear sense of stimulation that dominates the experience.
Cardiovascular effects become prominent — tachycardia, noticeable vasoconstriction, and elevated blood pressure. Bruxism (jaw clenching), excessive sweating, and appetite suppression are typical. Compulsive redosing urge may emerge as effects begin to wane.
Sleep is impossible for the duration and several hours beyond. Functional impairment increases due to overconfidence and reduced impulse control despite subjective feelings of enhanced performance.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch enhancement · Sound sensitivity · Auditory hallucinations · External hallucinations · Shadow people
Shadow people
Pupil dilation · Insomnia · Physical fatigue · Dry mouth · Restlessness · Excessive sweating · Muscle tension · Dehydration sensation · Body high · Heart rate perception changes · Temperature dysregulation · Spontaneous body sensations · Nausea · Bruxism · Sexual arousal enhancement · Bodily lightness · Respiratory stimulation · Tingling / electric sensations · Trembling · Tactile euphoria · Involuntary body movements · Headache · Vibrations / buzzing · Dizziness · Motor control impairment · Vomiting · Tactile hallucination
Dry mouth · Restlessness · Excessive sweating · Muscle tension · Dehydration sensation · Body high · Heart rate perception changes · Spontaneous body sensations · Nausea · Bruxism · Sexual arousal enhancement · Bodily lightness · Respiratory stimulation · Tingling / electric sensations · Trembling · Tactile euphoria · Involuntary body movements · Headache · Vibrations / buzzing · Dizziness · Motor control impairment · Vomiting · Tactile hallucination
Motivation suppression · Focus enhancement · Motivation enhancement · Information processing enhancement · Analysis enhancement · Cognitive dysphoria · Immersion enhancement · Novelty enhancement · Pattern recognition enhancement · Thought organization · Language enhancement · Thought deceleration · Aesthetic enhancement · Conceptual thinking · Multiple thought streams · Thought connectivity · Memory enhancement · Creativity enhancement · Humor enhancement · Cognitive impairment · Confusion · Openness enhancement · Thought disorganization · Thought loops · Delusions · Delirium
Information processing enhancement · Analysis enhancement · Cognitive dysphoria · Immersion enhancement · Novelty enhancement · Pattern recognition enhancement · Thought organization · Language enhancement · Thought deceleration · Aesthetic enhancement · Conceptual thinking · Multiple thought streams · Thought connectivity · Memory enhancement · Creativity enhancement · Humor enhancement · Cognitive impairment · Confusion · Openness enhancement · Thought disorganization · Thought loops · Delirium
Anhedonia · Dysphoria · Emotional enhancement · Empathy enhancement · Emotional lability · Mania
Empathy enhancement · Emotional lability
Disinhibition · Ego inflation · Flow state · Social connection · Automaticity · Trust enhancement
Automaticity · Trust enhancement
Timeline
First alerts appear as subtle mood lift, mild restlessness, and faint physical energy. Heart rate begins to increase.
Stimulation builds steadily with increasing wakefulness, emerging euphoria, and growing confidence. Cardiovascular activation becomes noticeable — elevated heart rate, vasoconstriction.
Maximum stimulation with pronounced cognitive euphoria, motivation enhancement, thought acceleration, and strong wakefulness. Cardiovascular effects are at their most intense. Compulsive redosing urge may emerge as the peak begins to plateau.
Effects sustain at diminished but clearly perceptible intensity. Stimulation persists with waning euphoria. Sympathomimetic effects (tachycardia, sweating, bruxism) continue.
Gradual return toward baseline with fading stimulation. Irritability, restlessness, and early dysphoria emerge. Appetite begins to return.
Residual effects include low mood, fatigue, reduced motivation, and disrupted sleep architecture. Anhedonia and mild depression may persist for 12–24 hours after strong doses. Appetite returns but may remain suppressed.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- —
Toxicity
Acute Toxicity
At high doses, methcathinone can cause seizures, cardiovascular stress, and death. Preparations synthesized with potassium permanganate are more acutely toxic than the pure compound, because the manganese contamination adds its own toxicity.[25] No human lethal dose data exist and no therapeutic index has been established.safety citation needed
Monoaminergic Neurotoxicity
Both forms of the molecule damage dopamine-producing nerve cells in animal models. The more potent form additionally damages serotonin-producing nerve cells — a property linked to the N-methyl group rather than the base cathinone structure.[26]
Brain imaging in four abstinent users found a 24% reduction in DAT density in the caudate and 16% in the putamen — areas critical for movement and motivation.[9] Animal studies also found learning and memory decline and structural damage to prefrontal brain connections.[24]
Manganese Encephalopathy (IV Route)
Intravenous use of methcathinone prepared by potassium permanganate oxidation of pseudoephedrine introduces manganese contamination that causes permanent, largely irreversible parkinsonism. This is the single most dangerous documented consequence of methcathinone use.
The syndrome appears within months of regular IV use[11][15] and causes slowed movement, abnormal posture, freezing gait, speech difficulties, tremor, and rigidity.[7][27] It has been documented across Estonia, Latvia, Ukraine, Poland, and Ireland.[13][14]
This parkinsonism is mechanistically distinct from Parkinson's disease and does not respond to standard treatment. L-DOPA does not work,[7][10] chelation is generally ineffective,[15] and the condition is largely permanent.[14] Parkinsonian features occur in approximately half of long-term IV users,[28] with cognitive consequences including decision impairment[29] and neuropsychological deficits.[30][31]
Psychological Risks
Agitation, anxiety, paranoia, and hallucinations are documented psychiatric effects, particularly with heavy or chronic use.[8][5][32] Acute psychosis can emerge during binges.
Prolonged binges carry additional psychiatric consequences: sleep deprivation, malnutrition, and social deterioration.[16][5] As a potent dopamine-releasing agent, methcathinone may trigger or worsen psychotic episodes in vulnerable individuals.inferred
Tolerance & Dependence
Dependence is documented in clinical case reports, with compulsive IV use and tolerance escalation described throughout the Eastern European epidemic literature.[16] Animal studies show repeated exposure produces both tolerance and sensitization simultaneously — the pleasure fades while the motivational drive intensifies.[23]
No human withdrawal has been specifically characterized; fatigue, low mood, and excessive sleep are expected by analogy with the stimulant class, but substance-specific data are absent.inferred Cross-tolerance with amphetamine, methamphetamine, and other dopamine-releasing stimulants is expected from animal studies.[18]
Drug Interactions
No drug interaction studies specific to methcathinone exist; all assessments are inferred from pharmacological class.inferred The most dangerous predicted interaction is with monoamine oxidase inhibitors (MAOIs): combining them blocks dopamine and norepinephrine breakdown, causing uncontrolled accumulation that risks dangerous blood pressure spikes, overheating, seizures, and death.
Co-use with other stimulants (Amphetamine, cocaine, MDMA) adds cardiovascular and overheating risk.[21][22] Serotonergic drugs (SSRIs, SNRIs, triptans) may trigger serotonin syndrome — potentially life-threatening overheating and seizures. Tricyclic antidepressants and SNRIs may amplify cardiovascular effects through overlapping norepinephrine mechanisms.
Contraindications
No substance-specific contraindication data exist; the following are inferred from pharmacological class.inferred
Absolute contraindications (class inference):
- Concurrent MAOI therapy — risk of dangerous blood pressure crisis and serotonin syndrome
- Severe heart disease, uncontrolled high blood pressure, or irregular heartbeat — methcathinone's stimulant effects impose acute cardiovascular stress
Relative contraindications (class inference):
- History of psychosis or schizophrenia — dopamine release may trigger or worsen psychotic episodes
- Concurrent stimulant use — additive cardiovascular and overheating risk
- Pregnancy — no reproductive toxicity data exist; class-level risk appliessafety citation needed
Harm Reduction[edit]
Forms & Identification
Methcathinone hydrochloride appears as a white or off-white crystalline powder. The critical identification concern is not substitution but contamination: methcathinone synthesized by permanganate oxidation of pseudoephedrine inevitably contains residual manganese, and no field test can quantify how much.
Reagent testing can confirm a cathinone is present but cannot distinguish a clean batch from a contaminated one. For IV users, the absence of any practical purity test means every injection carries unknown manganese exposure.
Guidelines
- Test material with a reagent kit to confirm cathinone presence — this rules out gross substitution but will not detect manganese contamination
- Start with the lowest plausible dose and wait for full onset before considering redosing
- Pre-set a hard redosing limit and remove excess material from reach before the session begins
- Avoid intravenous administration — this route carries the highest risk of manganese-induced brain damage from permanganate-synthesized product
- Eat before dosing, as appetite suppression is likely; stay hydrated without overhydrating
- Monitor heart rate; stop activity and seek help if chest pain, severe headache, or irregular heartbeat develops
Set & Setting
The stimulant profile favors calm environments where elevated heart rate and restless energy can be managed. Overstimulating or socially pressured settings amplify anxiety and paranoid ideation quickly.
A trusted, sober companion reduces risk during first use. Given the strong redosing urge, setting a firm dose limit before the session and physically removing excess material lowers the likelihood of unplanned escalation.
Aftercare & integration. The stimulant comedown brings fatigue, low mood, irritability, and disrupted sleep. Avoid redosing to offset the crash. Eat nutritious food as appetite returns; adequate hydration and B vitamins support recovery.
Sleep disruption may persist for one to two days. Avoid caffeine and additional stimulants during recovery. If low mood or anhedonia persists beyond a few days, reassess use patterns rather than dosing through it.
Recovery & Support
Methcathinone dependence follows the stimulant pattern: compulsive redosing escalates into binges, tolerance drives dose increases, and the crash deepens with chronic use. Recognition of this cycle is the first step toward change.
Professional support through addiction medicine or behavioral health provides the most evidence-based path. Cognitive behavioral therapy is effective for stimulant use disorders. Peer support communities — including SMART Recovery and 12-step programs — offer structured ongoing support.
For individuals in the IV methcathinone population who may have developed manganese-related neurological symptoms, neurological evaluation is essential — motor and cognitive impairments may require specialized rehabilitation.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain, severe headache, or irregular heartbeat
- Seizures or loss of consciousness
- Body temperature so high it can be felt through clothing
- Extreme agitation, violent behavior, or psychosis with loss of contact with reality
- Breathing difficulties
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 4. Do not restrain unless there is immediate danger of self-harm
- 5. Do not induce vomiting
- 6. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher:
- The substance taken (methcathinone or ephedrone), estimated amount, time of last dose, and route of administration
- Current symptoms — especially chest pain, seizures, temperature, or altered consciousness
- Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency
Legal Status[edit]
Methcathinone is internationally controlled and carries no accepted medical use in any jurisdiction.
Legal status changes frequently. This information reflects known law as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before relying on this information.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency scheduled May 1, 1992; permanently placed in Schedule I in 1993. No accepted medical use; high abuse potential[6] |
| International | Schedule I (1971 UN Convention on Psychotropic Substances) | Listed under the Convention framework[33] |
| United Kingdom | Class B (Misuse of Drugs Act 1971); Schedule 1 (MDR 2001) | Controlled under synthetic cathinone generic definition[4] |
| Australia | Schedule 9 (Poisons Standard) | Prohibited substance; no permitted use outside approved researchcitation needed |
| Canada | Controlled (CDSA) | Scheduled under the Controlled Drugs and Substances Actcitation needed |
references
- [1] ^abGlennon RA, Yousif M, Naiman N, Kalix P (1987) Methcathinone: a new and potent amphetamine-like agent. — Pharmacology, Biochemistry, and Behavior PMID:3575369
- [2] ^abcSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [3] ^abcDavies RA, Baird TR, Nguyen VT, Ruiz B, Sakloth F, Eltit JM, Negus SS, Glennon RA (2020) Investigation of the Optical Isomers of Methcathinone, and Two Achiral Analogs, at Monoamine Transporters and in Intracranial Self-Stimulation Studies in Rats. — ACS Chemical Neuroscience doi:10.1021/acschemneuro.9b00617
- [4]
- [5]
- [6]